Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2003 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/1697 http://dx.doi.org/10.1590/S1413-86702003000200003 |
Resumo: | BACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections. |
id |
UFSP_a2ed11db461b7dd85c3f7c672ba4a6d7 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/1697 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Petrilli, Antonio Sergio [UNIFESP]Cypriano, Monica [UNIFESP]Dantas, Lenice Silva [UNIFESP]Lee, Lúcia Martino [UNIFESP]Luisi, Maria Flávio Augusto Vercillo [UNIFESP]Silva, Katia Veronica Torres B. [UNIFESP]Pereira, Carlos Alberto Pires [UNIFESP]Universidade Federal de São Paulo (UNIFESP)2015-06-14T13:29:59Z2015-06-14T13:29:59Z2003-04-01Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 7, n. 2, p. 111-120, 2003.1413-8670http://repositorio.unifesp.br/handle/11600/1697http://dx.doi.org/10.1590/S1413-86702003000200003S1413-86702003000200003.pdfS1413-8670200300020000310.1590/S1413-86702003000200003BACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections.Federal University of São Paulo Division of Infectious Disease Pediatric Oncology InstituteUNIFESP, Division of Infectious Disease Pediatric Oncology InstituteSciELO111-120engBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious DiseasesFeverneutropenialeukemialymphomaticarcillinceftriaxoneEvaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphomainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALS1413-86702003000200003.pdfapplication/pdf36631${dspace.ui.url}/bitstream/11600/1697/1/S1413-86702003000200003.pdf5a19091357048de92f231998bfb5ab65MD51open accessTEXTS1413-86702003000200003.pdf.txtS1413-86702003000200003.pdf.txtExtracted texttext/plain33399${dspace.ui.url}/bitstream/11600/1697/21/S1413-86702003000200003.pdf.txt49202ab4ae1db74c0ac13368608fbbc9MD521open accessTHUMBNAILS1413-86702003000200003.pdf.jpgS1413-86702003000200003.pdf.jpgIM Thumbnailimage/jpeg6222${dspace.ui.url}/bitstream/11600/1697/23/S1413-86702003000200003.pdf.jpg9b0fe3daad989dcf94c571a62eb51b86MD523open access11600/16972023-06-05 19:55:19.734open accessoai:repositorio.unifesp.br:11600/1697Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-06-05T22:55:19Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
title |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
spellingShingle |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma Petrilli, Antonio Sergio [UNIFESP] Fever neutropenia leukemia lymphoma ticarcillin ceftriaxone |
title_short |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
title_full |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
title_fullStr |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
title_full_unstemmed |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
title_sort |
Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma |
author |
Petrilli, Antonio Sergio [UNIFESP] |
author_facet |
Petrilli, Antonio Sergio [UNIFESP] Cypriano, Monica [UNIFESP] Dantas, Lenice Silva [UNIFESP] Lee, Lúcia Martino [UNIFESP] Luisi, Maria Flávio Augusto Vercillo [UNIFESP] Silva, Katia Veronica Torres B. [UNIFESP] Pereira, Carlos Alberto Pires [UNIFESP] |
author_role |
author |
author2 |
Cypriano, Monica [UNIFESP] Dantas, Lenice Silva [UNIFESP] Lee, Lúcia Martino [UNIFESP] Luisi, Maria Flávio Augusto Vercillo [UNIFESP] Silva, Katia Veronica Torres B. [UNIFESP] Pereira, Carlos Alberto Pires [UNIFESP] |
author2_role |
author author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Petrilli, Antonio Sergio [UNIFESP] Cypriano, Monica [UNIFESP] Dantas, Lenice Silva [UNIFESP] Lee, Lúcia Martino [UNIFESP] Luisi, Maria Flávio Augusto Vercillo [UNIFESP] Silva, Katia Veronica Torres B. [UNIFESP] Pereira, Carlos Alberto Pires [UNIFESP] |
dc.subject.eng.fl_str_mv |
Fever neutropenia leukemia lymphoma ticarcillin ceftriaxone |
topic |
Fever neutropenia leukemia lymphoma ticarcillin ceftriaxone |
description |
BACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections. |
publishDate |
2003 |
dc.date.issued.fl_str_mv |
2003-04-01 |
dc.date.accessioned.fl_str_mv |
2015-06-14T13:29:59Z |
dc.date.available.fl_str_mv |
2015-06-14T13:29:59Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 7, n. 2, p. 111-120, 2003. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/1697 http://dx.doi.org/10.1590/S1413-86702003000200003 |
dc.identifier.issn.none.fl_str_mv |
1413-8670 |
dc.identifier.file.none.fl_str_mv |
S1413-86702003000200003.pdf |
dc.identifier.scielo.none.fl_str_mv |
S1413-86702003000200003 |
dc.identifier.doi.none.fl_str_mv |
10.1590/S1413-86702003000200003 |
identifier_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 7, n. 2, p. 111-120, 2003. 1413-8670 S1413-86702003000200003.pdf S1413-86702003000200003 10.1590/S1413-86702003000200003 |
url |
http://repositorio.unifesp.br/handle/11600/1697 http://dx.doi.org/10.1590/S1413-86702003000200003 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Brazilian Journal of Infectious Diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
111-120 |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/1697/1/S1413-86702003000200003.pdf ${dspace.ui.url}/bitstream/11600/1697/21/S1413-86702003000200003.pdf.txt ${dspace.ui.url}/bitstream/11600/1697/23/S1413-86702003000200003.pdf.jpg |
bitstream.checksum.fl_str_mv |
5a19091357048de92f231998bfb5ab65 49202ab4ae1db74c0ac13368608fbbc9 9b0fe3daad989dcf94c571a62eb51b86 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764230483509248 |